-
公开(公告)号:DK3795167T3
公开(公告)日:2022-08-29
申请号:DK20204314
申请日:2017-09-15
Applicant: LEIDOS INC
Inventor: GUTIERREZ GABRIEL M , KOTRAIAH VINAYAKA , PANNUCCI JAMES , AYALA RAMSES
-
公开(公告)号:AU2018273958B2
公开(公告)日:2022-07-21
申请号:AU2018273958
申请日:2018-05-25
Applicant: LEIDOS INC
Inventor: GUTIERREZ GABRIEL M , KOTRAIAH VINAYAKA , PHARES TIMOTHY , PANNUCCI JAMES
IPC: A61K38/17 , C07K14/705
Abstract: This disclosure provides peptides which have a strong affinity for the checkpoint receptor "programmed death 1" (PD-1). These peptides block the interaction of PD-1 with its ligand PD-L1 as well as the interaction of CTLA4 with CD86 and can therefore be used for various therapeutic purposes, such as inhibiting the progression of a hyperproliferative disorder, including cancer; treating infectious diseases; enhancing a response to vaccination; treating sepsis; and promoting hair re-pigmentation or lightening of pigmented skin lesions.
-
公开(公告)号:DK3512536T3
公开(公告)日:2020-11-23
申请号:DK17778394
申请日:2017-09-15
Applicant: LEIDOS INC
Inventor: GUTIERREZ GABRIEL M , PANNUCCI JAMES , AYALA RAMSES , KOTRAIAH VINAYAKA
-
公开(公告)号:AU2017325866A1
公开(公告)日:2019-04-18
申请号:AU2017325866
申请日:2017-09-15
Applicant: LEIDOS INC
Inventor: GUTIERREZ GABRIEL M , KOTRAIAH VINAYAKA , PANNUCCI JAMES , AYALA RAMSES
Abstract: This disclosure provides peptides which have a strong affinity for the checkpoint receptor "programmed death 1" (PD-1). These peptides block the interaction of PD-1 with its ligand PDL1 and can therefore be used for various therapeutic purposes, such as inhibiting the progression of a hyperproliferative disorder, including cancer, treating infectious diseases, enhancing a response to vaccination, and treating sepsis.
-
公开(公告)号:CA3064023A1
公开(公告)日:2018-11-29
申请号:CA3064023
申请日:2018-05-25
Applicant: LEIDOS INC
Inventor: GUTIERREZ GABRIEL M , KOTRAIAH VINAYAKA , PHARES TIMOTHY , PANNUCCI JAMES
IPC: C07K14/705 , A61K38/17
Abstract: This disclosure provides peptides which have a strong affinity for the checkpoint receptor "programmed death 1" (PD-1). These peptides block the interaction of PD-1 with its ligand PD-L1 as well as the interaction of CTLA4 with CD86 and can therefore be used for various therapeutic purposes, such as inhibiting the progression of a hyperproliferative disorder, including cancer; treating infectious diseases; enhancing a response to vaccination; treating sepsis; and promoting hair re-pigmentation or lightening of pigmented skin lesions.
-
-
-
-